ICCC

+ Watchlist + Portfolio

ImmuCell Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.60
52-Week Range: $4.52 – $12.10
Market Cap: $88.55M
P/E (TTM): 139.29
EPS (TTM): 0.07
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.82
PEG Ratio: —
Return on Equity: 2.57%
Return on Assets: 6.25%
Gross Margin: 40.32%
Operating Margin: 26.93%
Profit Margin: 2.57%
Current Ratio: 4.75
Debt/Equity: 0.40
Total Debt: $12.45M
Free Cash Flow: $3.08M
Revenue Growth: 11.50%
Earnings Growth: 259.90%
Enterprise Value: $92.14M

ICCC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$18.57M	$17.47M	$26.49M	$27.64M
Cost of Revenue	$10.92M	$13.60M	$18.55M	$16.20M
Gross Profit	$7.65M	$3.87M	$7.94M	$11.45M
Research & Development	$4.49M	$4.39M	$3.90M	$3.04M
Selling, General & Admin	$5.45M	$5.22M	$5.68M	$6.75M
Operating Expenses	$9.95M	$9.62M	$9.58M	$9.80M
Operating Income	-$2.30M	-$5.75M	-$1.64M	$1.65M
EBITDA	$349.99K	-$2.60M	$1.07M	$2.14M
Pretax Income	-$2.49M	-$5.77M	-$2.15M	-$1.03M
Income Tax	$7.67K	$4.63K	$10.06K	$11.57K
Net Income	-$2.49M	-$5.77M	-$2.16M	-$1.04M
Diluted EPS	-0.32	-0.75	-0.26	-0.12
Diluted Shares	7.75M	7.75M	8.17M	9.03M

ICCC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.79M	$978.74K	$3.76M	$3.81M
Receivables	$1.80M	$2.23M	$3.81M	$3.45M
Inventory	$6.04M	$7.81M	$7.11M	$9.27M
Current Assets	$13.99M	$11.47M	$15.04M	$16.94M
Total Assets	$44.86M	$43.81M	$45.10M	$42.53M
Current Liabilities	$3.07M	$4.20M	$4.41M	$3.98M
Long-Term Debt	$9.19M	$10.54M	$9.04M	$7.49M
Total Debt	$12.48M	$16.69M	$15.10M	$13.19M
Total Liabilities	$14.48M	$18.82M	$17.58M	$15.48M
Retained Earnings	-$6.23M	-$12.01M	-$14.16M	-$15.20M
Shareholders' Equity	$30.38M	$24.99M	$27.52M	$27.06M
Working Capital	$10.92M	$7.27M	$10.63M	$12.97M
Net Debt	$4.44M	$10.99M	$6.78M	$5.29M

ICCC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.54M	-$4.67M	$357.90K	$2.48M
Capital Expenditure	-$3.98M	-$1.89M	-$465.73K	-$1.25M
Free Cash Flow	-$5.52M	-$6.57M	-$107.82K	$1.22M
Depreciation & Amortisation	$2.49M	$2.72M	$2.69M	$2.73M
Stock-Based Compensation	$266.24K	$368.87K	$325.55K	$295.87K
Investing Cash Flow	-$3.96M	-$1.89M	-$461.23K	-$1.21M
Financing Cash Flow	$1.11M	$1.75M	$2.88M	-$1.21M
Net Change in Cash	-$4.39M	-$4.81M	$2.78M	$48.60K

ICCC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$8.07M	$6.44M	$5.51M	$7.63M	$10.36M	$7.19M
Cost of Revenue	$4.71M	$3.63M	$3.14M	$4.72M	$5.70M	$4.75M
Gross Profit	$3.35M	$2.82M	$2.36M	$2.91M	$4.66M	$2.44M
Research & Development	$756.85K	$831.86K	$694.31K	$758.86K	$317.69K	$119.65K
Selling, General & Admin	$1.48M	$1.42M	$1.65M	$2.21M	$2.37M	$2.38M
Operating Expenses	$2.24M	$2.25M	$2.34M	$2.97M	$2.69M	$502.29K
Operating Income	$1.12M	$569.56K	$20.07K	-$57.96K	$1.97M	$1.93M
EBITDA	$2.24M	$1.29M	$648.73K	-$2.04M	$2.58M	$2.44M
Pretax Income	$1.45M	$503.78K	-$135.29K	-$2.85M	$1.95M	$1.88M
Income Tax	$1.90K	$1.90K	$4.46K	$3.31K	$12.52K	$45.95K
Net Income	$1.45M	$501.88K	-$139.75K	-$2.85M	$1.94M	$1.83M
Diluted EPS	0.16	0.06	-0.02	-0.31	0.21	0.20
Diluted Shares	8.98M	9.03M	9.05M	9.05M	9.05M	9.19M

ICCC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$4.60M	$6.00M	$3.89M	$3.81M	$6.81M	$8.86M
Receivables	$3.40M	$2.42M	$2.61M	$3.45M	$2.73M	$2.90M
Inventory	$7.36M	$8.29M	$9.80M	$9.27M	$8.67M	$9.08M
Current Assets	$15.92M	$17.14M	$16.83M	$16.94M	$18.86M	$21.08M
Total Assets	$45.62M	$46.72M	$45.73M	$42.53M	$44.11M	$46.63M
Current Liabilities	$3.87M	$4.45M	$4.00M	$3.98M	$3.91M	$4.44M
Long-Term Debt	$8.65M	$8.26M	$7.90M	$7.49M	$7.07M	$6.80M
Total Debt	$14.66M	$14.27M	$13.61M	$13.19M	$12.78M	$12.45M
Total Liabilities	$16.63M	$16.85M	$15.93M	$15.48M	$14.97M	$15.26M
Retained Earnings	-$12.72M	-$12.21M	-$12.35M	-$15.20M	-$13.26M	-$11.43M
Shareholders' Equity	$28.99M	$29.87M	$29.80M	$27.06M	$29.14M	$31.37M
Working Capital	$12.05M	$12.69M	$12.83M	$12.97M	$14.95M	$16.64M
Net Debt	$5.57M	$3.80M	$5.60M	$5.29M	$1.89M	—

ICCC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$1.57M	$1.60M	-$1.18M	$482.54K	$3.57M	$3.02M
Capital Expenditure	-$329.05K	-$155.16K	-$593.92K	-$172.31K	-$177.23K	-$733.94K
Free Cash Flow	$1.24M	$1.45M	-$1.78M	$310.24K	$3.40M	$2.29M
Depreciation & Amortisation	$675.97K	$668.23K	$679.09K	$706.32K	$528.29K	$470.62K
Stock-Based Compensation	$52.22K	$66.71K	$73.16K	$103.78K	$137.95K	$239.87K
Investing Cash Flow	-$329.05K	-$125.93K	-$592.02K	-$167.31K	-$167.23K	-$733.94K
Financing Cash Flow	-$403.65K	-$76.45K	-$337.69K	-$394.60K	-$400.00K	-$237.56K
Net Change in Cash	$841.14K	$1.40M	-$2.11M	-$79.37K	$3.01M	$2.05M

Market Snapshot

About

ImmuCell Corporation is an animal health company focused on developing and commercializing products that improve the health and productivity of dairy and beef cattle. The company's primary product is First Defense, a line of products providing passive antibody protection against scours in newborn calves. ImmuCell is also developing Mast Out, a novel treatment for subclinical mastitis in lactating dairy cows that could serve as an alternative to traditional antibiotics. The company manufactures its products at its facility in Maine and distributes them throughout the United States and internationally.